| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 11% | $343,082,387 | 17,540,089 | T. Rowe Price Investment Management, Inc. | 31 Dec 2025 | |||
| JANUS HENDERSON GROUP PLC | 10% | +3% | $186,530,638 | +$4,433,901 | 14,745,505 | +2.4% | JANUS HENDERSON GROUP PLC | 30 Sep 2025 |
| BlackRock, Inc. | 5.8% | $49,662,986 | 6,577,879 | BlackRock, Inc. | 31 Mar 2025 | |||
| Atlas Venture Fund XI, L.P. | 4% | $72,275,396 | 5,713,470 | Atlas Venture Associates XI, L.P. | 30 Sep 2025 | |||
| Forbion Capital Fund IV Cooperatief U.A. | 4.8% | $40,774,115 | 5,400,545 | ForDyne B.V. | 31 Mar 2025 | |||
| FMR LLC | 4.6% | -41% | $39,224,470 | -$21,152,359 | 5,195,294 | -35% | FMR LLC | 31 Mar 2025 |
| RTW INVESTMENTS, LP | 1.5% | -72% | $12,763,781 | -$26,636,959 | 1,690,567 | -68% | RTW Investments, LP | 31 Mar 2025 |
| Point72 Asset Management, L.P. | 1.5% | -72% | $12,603,532 | -$26,630,775 | 1,669,342 | -68% | Point72 Asset Management, L.P. | 31 Mar 2025 |
As of 30 Sep 2025, 205 institutional investors reported holding 155,774,921 shares of Dyne Therapeutics, Inc. - COMMON STOCK (DYN). This represents 95% of the company’s total 163,926,065 outstanding shares.
The largest institutional shareholders of Dyne Therapeutics, Inc. - COMMON STOCK (DYN) together control 70% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 9% | 14,745,505 | +56% | 0.09% | $186,489,080 |
| VANGUARD GROUP INC | 6% | 9,760,414 | +28% | 0% | $123,469,238 |
| BlackRock, Inc. | 5.9% | 9,634,909 | +19% | 0% | $121,881,599 |
| Atlas Venture Life Science Advisors, LLC | 5.6% | 9,130,465 | 0% | 15% | $115,500,382 |
| FCPM III SERVICES B.V. | 3.3% | 5,462,846 | 0% | 14% | $69,105,002 |
| FMR LLC | 3.3% | 5,401,916 | +2.1% | 0% | $68,334,236 |
| STATE STREET CORP | 3.2% | 5,268,917 | +57% | 0% | $66,651,800 |
| Siren, L.L.C. | 2.9% | 4,729,174 | -2.2% | 2.3% | $59,824,051 |
| TCG Crossover Management, LLC | 2.8% | 4,615,144 | +23% | 2.9% | $58,381,572 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.2% | 3,554,000 | +11% | 0.07% | $44,958,100 |
| CITADEL ADVISORS LLC | 2.1% | 3,413,435 | +262% | 0.03% | $43,179,952 |
| JPMORGAN CHASE & CO | 2.1% | 3,365,245 | +9% | 0% | $42,570,350 |
| ARMISTICE CAPITAL, LLC | 1.9% | 3,064,000 | +20% | 1.2% | $38,759,600 |
| MARSHALL WACE, LLP | 1.8% | 3,013,377 | +573% | 0.04% | $38,119,219 |
| RTW INVESTMENTS, LP | 1.8% | 2,890,567 | +71% | 0.45% | $36,565,673 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 2,867,605 | +27% | 0% | $36,282,012 |
| T. Rowe Price Investment Management, Inc. | 1.7% | 2,812,422 | +57% | 0.02% | $35,578,000 |
| Vestal Point Capital, LP | 1.7% | 2,775,000 | +281% | 1.6% | $35,103,750 |
| BRAIDWELL LP | 1.7% | 2,730,481 | -17% | 1% | $34,540,585 |
| Frazier Life Sciences Management, L.P. | 1.7% | 2,718,105 | +80% | 1% | $34,384,028 |
| Saturn V Capital Management LP | 1.6% | 2,674,469 | +84% | 7.4% | $33,832,033 |
| Vivo Capital, LLC | 1.6% | 2,614,960 | +135% | 2.7% | $33,079,244 |
| Logos Global Management LP | 1.5% | 2,400,000 | +26% | 3% | $30,360,000 |
| ORBIMED ADVISORS LLC | 1.4% | 2,314,184 | +124% | 0.7% | $29,274,428 |
| VR ADVISER, LLC | 1.3% | 2,173,913 | 0% | 1.5% | $27,499,999 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 1,577,679 | $30,859,490 | +$15,313,387 | $19.56 | 11 |
| 2025 Q3 | 155,774,921 | $1,970,440,036 | +$381,733,655 | $12.65 | 205 |
| 2025 Q2 | 128,613,808 | $1,225,730,095 | +$58,226,795 | $9.52 | 196 |
| 2025 Q1 | 121,788,688 | $1,284,330,838 | -$75,923,420 | $10.46 | 202 |
| 2024 Q4 | 111,583,671 | $2,629,099,615 | -$30,309,924 | $23.56 | 197 |
| 2024 Q3 | 111,996,612 | $4,017,939,785 | -$15,655,202 | $35.92 | 201 |
| 2024 Q2 | 110,971,178 | $3,915,828,772 | +$557,144,607 | $35.29 | 192 |
| 2024 Q1 | 95,304,931 | $2,705,680,350 | +$815,898,874 | $28.39 | 167 |
| 2023 Q4 | 38,782 | $515,801 | -$441,095 | $13.30 | 1 |
| 2023 Q3 | 59,888,832 | $536,594,078 | +$3,884,227 | $8.96 | 114 |
| 2023 Q2 | 58,994,238 | $663,650,781 | +$48,611,806 | $11.25 | 116 |
| 2023 Q1 | 54,595,706 | $628,353,131 | +$56,445,081 | $11.52 | 124 |
| 2022 Q4 | 49,699,094 | $575,995,247 | +$50,399,191 | $11.59 | 110 |
| 2022 Q3 | 42,676,458 | $541,981,153 | -$9,307,384 | $12.70 | 95 |
| 2022 Q2 | 46,398,777 | $318,776,640 | -$7,882,607 | $6.87 | 84 |
| 2022 Q1 | 46,935,331 | $452,342,690 | -$3,420,501 | $9.64 | 87 |
| 2021 Q4 | 47,782,959 | $568,117,037 | +$18,785,223 | $11.89 | 89 |
| 2021 Q3 | 32,202,637 | $523,045,164 | -$17,975,014 | $16.24 | 79 |
| 2021 Q2 | 32,884,008 | $691,907,735 | +$24,394,747 | $21.04 | 73 |
| 2021 Q1 | 31,379,585 | $487,295,000 | +$66,025,917 | $15.53 | 72 |
| 2020 Q4 | 25,342,341 | $531,500,805 | +$16,521,572 | $21.00 | 64 |
| 2020 Q3 | 24,223,914 | $487,607,000 | +$487,606,790 | $20.19 | 48 |